MiNK Therapeutics Releases New Clinical Data on agenT-797 and N-803 Combination Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: Newsfilter
- Clinical Data Presentation: MiNK Therapeutics showcased clinical data on the combination therapy of agenT-797 and N-803 at the American Thoracic Society conference, demonstrating effectiveness against unresolving Coccidioides immitis infection, potentially offering new treatment options for critically ill pneumonia patients.
- Immune Recovery Observations: Following treatment with N-803 and agenT-797, the patient exhibited effective suppression of fungal and bacterial pathogens, with immune cells recruited to the lungs, indicating that this therapy may help restore immune function and improve outcomes in critically ill patients.
- Research Prospects: MiNK Therapeutics is initiating a randomized Phase 2 clinical trial to evaluate the efficacy of agenT-797 compared to standard care, aiming to provide more effective treatment options for patients with severe acute lung injury, thus advancing clinical practice.
- Strategic Significance: These findings not only support MiNK's therapeutic potential in severe lung injury but also highlight the critical role of iNKT cells in addressing immune dysfunction and persistent infections, potentially paving the way for new treatments in cancer and autoimmune diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.870
Low
35.00
Averages
35.00
High
35.00
Current: 10.870
Low
35.00
Averages
35.00
High
35.00
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Noetik's TARIO-2 Platform Reveals Tumor Microenvironment Patterns
- Significant Clinical Response: Among 113 patients treated with BOT+BAL, the AI-identified subgroup exhibited a 64% response rate compared to just 9% in the remaining cohort, highlighting TARIO-2's potential in identifying patients likely to benefit from treatment.
- Improved Survival Rates: In the MSS metastatic colorectal cancer cohort without active liver metastases, the AI-identified subgroup had a median overall survival not reached, with a hazard ratio of 0.18, indicating TARIO-2's significant predictive power for survival outcomes.
- Innovative Technology Application: The TARIO-2 model analyzes standard H&E pathology images to extract biologically relevant tumor microenvironment features, offering a patient stratification strategy that does not rely on complex tissue profiling, which could transform clinical practices.
- Future Validation Plans: Agenus is set to present these findings at the 2026 ASCO Annual Meeting, aiming to validate TARIO-2 as an image-based biomarker strategy for BOT+BAL, thereby advancing the clinical development of immunotherapy.
See More
MiNK Therapeutics Releases New Clinical Data on agenT-797 and N-803 Combination Therapy
- Clinical Data Presentation: MiNK Therapeutics showcased clinical data on the combination therapy of agenT-797 and N-803 at the American Thoracic Society conference, demonstrating effectiveness against unresolving Coccidioides immitis infection, potentially offering new treatment options for critically ill pneumonia patients.
- Immune Recovery Observations: Following treatment with N-803 and agenT-797, the patient exhibited effective suppression of fungal and bacterial pathogens, with immune cells recruited to the lungs, indicating that this therapy may help restore immune function and improve outcomes in critically ill patients.
- Research Prospects: MiNK Therapeutics is initiating a randomized Phase 2 clinical trial to evaluate the efficacy of agenT-797 compared to standard care, aiming to provide more effective treatment options for patients with severe acute lung injury, thus advancing clinical practice.
- Strategic Significance: These findings not only support MiNK's therapeutic potential in severe lung injury but also highlight the critical role of iNKT cells in addressing immune dysfunction and persistent infections, potentially paving the way for new treatments in cancer and autoimmune diseases.
See More
MiNK Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: MiNK Therapeutics announced the initiation of a randomized Phase II clinical trial for acute lung injury in Q1 2026, with expectations for rapid early clinical data that supports its strategic development in pulmonary diseases.
- Strong Financial Position: As of the end of 2025, the company reported approximately $13.4 million in cash and cash equivalents, and after repaying $5.2 million in debt and raising $3 million, it ended the quarter with about $9.5 million, ensuring operational funding for at least the next 12 months.
- Partnership Strategy: The collaboration with C-Further aims to advance the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, providing nondilutive support and potential commercial economics, showcasing its strategic positioning in oncology treatment.
- Survival Rate Data: At the AACR meeting, MiNK reported Phase II data in gastroesophageal cancer, with a median overall survival exceeding 23 months in the immune-primed cohort, highlighting the treatment's potential and market prospects.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
MiNK Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: MiNK Therapeutics reported a Q1 GAAP EPS of -$0.57, beating expectations by $0.20, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of Q1 2026, MiNK's cash and cash equivalents stood at approximately $9.5 million, down from about $13.4 million as of December 31, 2025, suggesting some pressure on the company's financial management.
- Clinical Development: MiNK plans to release initial ARDS Phase II data in H2 2026, which could provide critical support for the company's future product development and market positioning.
- Strategic Collaboration: The partnership with C-Further led to a 60% surge in MiNK Therapeutics' stock price, enhancing the company's market visibility and potentially laying the groundwork for expansion in the pediatric cancer sector.
See More
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
Noetik's TARIO-2 Platform Reveals Tumor Microenvironment Patterns
- Significant Clinical Response: Among 113 patients treated with BOT+BAL, the AI-identified subgroup exhibited a 64% response rate compared to just 9% in the remaining cohort, highlighting TARIO-2's potential in identifying patients likely to benefit from treatment.
- Improved Survival Rates: In the MSS metastatic colorectal cancer cohort without active liver metastases, the AI-identified subgroup had a median overall survival not reached, with a hazard ratio of 0.18, indicating TARIO-2's significant predictive power for survival outcomes.
- Innovative Technology Application: The TARIO-2 model analyzes standard H&E pathology images to extract biologically relevant tumor microenvironment features, offering a patient stratification strategy that does not rely on complex tissue profiling, which could transform clinical practices.
- Future Validation Plans: Agenus is set to present these findings at the 2026 ASCO Annual Meeting, aiming to validate TARIO-2 as an image-based biomarker strategy for BOT+BAL, thereby advancing the clinical development of immunotherapy.
See More
MiNK Therapeutics Releases New Clinical Data on agenT-797 and N-803 Combination Therapy
- Clinical Data Presentation: MiNK Therapeutics showcased clinical data on the combination therapy of agenT-797 and N-803 at the American Thoracic Society conference, demonstrating effectiveness against unresolving Coccidioides immitis infection, potentially offering new treatment options for critically ill pneumonia patients.
- Immune Recovery Observations: Following treatment with N-803 and agenT-797, the patient exhibited effective suppression of fungal and bacterial pathogens, with immune cells recruited to the lungs, indicating that this therapy may help restore immune function and improve outcomes in critically ill patients.
- Research Prospects: MiNK Therapeutics is initiating a randomized Phase 2 clinical trial to evaluate the efficacy of agenT-797 compared to standard care, aiming to provide more effective treatment options for patients with severe acute lung injury, thus advancing clinical practice.
- Strategic Significance: These findings not only support MiNK's therapeutic potential in severe lung injury but also highlight the critical role of iNKT cells in addressing immune dysfunction and persistent infections, potentially paving the way for new treatments in cancer and autoimmune diseases.
See More
MiNK Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: MiNK Therapeutics announced the initiation of a randomized Phase II clinical trial for acute lung injury in Q1 2026, with expectations for rapid early clinical data that supports its strategic development in pulmonary diseases.
- Strong Financial Position: As of the end of 2025, the company reported approximately $13.4 million in cash and cash equivalents, and after repaying $5.2 million in debt and raising $3 million, it ended the quarter with about $9.5 million, ensuring operational funding for at least the next 12 months.
- Partnership Strategy: The collaboration with C-Further aims to advance the PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, providing nondilutive support and potential commercial economics, showcasing its strategic positioning in oncology treatment.
- Survival Rate Data: At the AACR meeting, MiNK reported Phase II data in gastroesophageal cancer, with a median overall survival exceeding 23 months in the immune-primed cohort, highlighting the treatment's potential and market prospects.
See More
Agenus Reports New Data on HCC Treatment
- Clinical Trial Results: Agenus' Phase 1b trial data reveals that in 19 patients with treatment-refractory hepatocellular carcinoma (HCC), the combination of BOT and BAL achieved an objective response rate of 17%, including one complete response and two partial responses, indicating potential efficacy in this challenging patient population.
- Survival Analysis: Among 18 efficacy-evaluable patients, the median overall survival was reported at 12.3 months, despite 47% of the cohort having ALBI grade 2 liver function, which typically indicates poorer prognosis, thus highlighting the potential of BOT and BAL in improving survival outcomes.
- Safety Assessment: The safety profile of BOT and BAL in HCC patients was consistent with prior studies, with 68% of patients experiencing immune-mediated adverse events and no treatment-related deaths, suggesting that the combination is manageable and suitable for further investigation.
- Future Research Directions: Investigators noted that the BOT and BAL combination demonstrated promising efficacy and manageable safety in post-immunotherapy HCC patients, supporting continued exploration in this area to assess its applicability in a broader patient population.
See More
MiNK Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: MiNK Therapeutics reported a Q1 GAAP EPS of -$0.57, beating expectations by $0.20, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of Q1 2026, MiNK's cash and cash equivalents stood at approximately $9.5 million, down from about $13.4 million as of December 31, 2025, suggesting some pressure on the company's financial management.
- Clinical Development: MiNK plans to release initial ARDS Phase II data in H2 2026, which could provide critical support for the company's future product development and market positioning.
- Strategic Collaboration: The partnership with C-Further led to a 60% surge in MiNK Therapeutics' stock price, enhancing the company's market visibility and potentially laying the groundwork for expansion in the pediatric cancer sector.
See More
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797 in Severe Lung Injury
- Trial Initiation: MiNK Therapeutics has launched a randomized Phase 2 clinical trial for agenT-797, targeting severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026, which will provide crucial insights for further development of the drug.
- Biological Rationale Strengthened: Presentations at AACR and ASGCT highlighted the durable survival and context-dependent activity of iNKT cells, particularly showing a 77% disease control rate and over 20 months of long-term survival in PD-1 refractory gastroesophageal cancer patients, underscoring its clinical potential.
- Capital Efficiency Improvement: MiNK secured approximately $1.1 million in non-dilutive funding through a collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, a strategy that not only reduces capital burden but also offers potential downstream commercial revenue opportunities.
- Financial Update: As of Q1 2026, MiNK reported approximately $9.5 million in cash and cash equivalents, down from $13.4 million at the end of 2025, although net loss slightly decreased to $2.74 million, indicating the company's ongoing commitment to advancing high-priority clinical programs.
See More
